Risk of infection with intravenous iron therapy

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1476-1480

  Maynor, Lena ^a   Brophy, Donald F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ferric gluconate; Intravenous iron; Iron dextran; Iron sucrose

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON; TRANSFERRIN;

BACTERIAL GROWTH; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; DRUG MECHANISM; HUMAN; INFECTION RISK; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; MEDLINE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANIMALS; BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; RISK;

EID: 34548174645     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K187     Document Type: Review

References (25)

1. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001;16:224-7.
2. Teehan GS, Bahdouch D, Ruthzaer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090-4.
3. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephol 1998;9:869-76.
4. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic hemodialysis patients: a multicentre prospective study. Nephrol Dial Transplant 1995;10:377-81.
5. Cavill I. Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 2003;18(suppl 8):viii24-8.
6. Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am 2004;18:1379-403.
7. Siah CW, Ombiga J, Adams LA, Trinder D, Olynyk JK. Normal iron metabolism and the pathophysiology of iron overload disorders. Clin Biochem Rev 2006;27:5-16.
8. Ward PP, Conneely OM. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 2004;17:203-8.
9. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005;62:2540-8.
10. Van Wyck DB, Bailie G, Arnoff G. Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 2002;39:426-32. DOI 10.1093/ndt/gfg1088
11. Deicher R, Ziai F, Cohen G, Müllner M, Hörl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64:728-36. DOI 10.1097/01.ASN/0000087087.61306.4A
12. Zager RA, Johnson ACM, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004;65:2108-12.
13. Zager RA, Johnson ACM, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-α mRNA production and TNF-α release. Am J Physiol Renal Physiol 2005;288:F290-7. DOI 10.1152/ajpreanl.00342. 2004
14. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-7.
15. Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004;17:57-60.
16. Sengöelge G, Kletzmayr J, Ferrara I, Perschl A, Hörl WH, Sunder-Plassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003;14:2639-44.
17. Cieri E. Does iron cause bacterial infections in patients with end stage renal disease? ANNA J 1999;26:591-6.
18. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-63.
19. Siefert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 1987;65:1015-24.
20. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, van Landuyt HW. Iron overload in hemodialysis patients increases the risk of bacteremia: a prospective study. Nephrol Dial Transplant 1990;5:130-4.
21. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of hemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989;4:883-7.
22. Brewster UC, Coca SG, Reilly RF, Perazella MA. Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology 2005;10:124-8.
23. Canziani MEF, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA. Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment. Artif Organs 2001;23:866-9.
24. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004;66:1193-8.
25. Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun 1985;47:774-9.